Ion Beam Applications SA IBA ( (GB:0GZK) ) has provided an update.
IBA has signed a term sheet with Apollo Hospitals for the installation of a Proteus ONE compact proton therapy system in India, with an option for a second system. This agreement strengthens the existing partnership between IBA and Apollo, which previously introduced the first proton beam therapy in India. The collaboration aims to enhance access to advanced cancer treatment in India, with the Proteus ONE systems expected to be operational by 2028. This move is anticipated to bolster IBA’s market position and expand Apollo’s capacity in proton therapy, reinforcing its status as a leader in cancer care.
More about Ion Beam Applications SA IBA
IBA (Ion Beam Applications S.A.) is the global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry. Based in Louvain-la-Neuve, Belgium, IBA employs around 2,000 people worldwide and is a certified B Corporation, listed on the EURONEXT stock exchange.
YTD Price Performance: -2.10%
Average Trading Volume: 741
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €384.9M
See more insights into 0GZK stock on TipRanks’ Stock Analysis page.